HIV Inhibitor Activity Prognosis Refined Taking Into Account the Drug Conformation at the Active Center of Enzyme

Author： Burlyaeva E. V.   Komardin P. V.   Yurkevich A. M.   Shvets V. I.  

Publisher： Springer Publishing Company

ISSN： 0091-150X

Source： Pharmaceutical Chemistry Journal, Vol.37, Iss.9, 2003-09, pp. : 460-462

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug Interactions of Tipranavir, a New HIV Protease Inhibitor

By  

Drug Metabolism Letters, Vol. 1, Iss. 1, 2007-01 ,pp. : 81-84

Bentham Science Publishers

Access to resources Recommend Favorite

Tipranavir: a protease inhibitor for multi-drug resistant HIV-1

By Best Brookie   Haubrich Richard  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 59-70

Informa Healthcare

Access to resources Recommend Favorite

Structure-Activity Relationships of HIV-1 Integrase Inhibitors - Enzyme- Ligand Interactions

By  

Current Medicinal Chemistry, Vol. 10, Iss. 18, 2003-09 ,pp. : 1795-1810

Bentham Science Publishers

Access to resources Recommend Favorite

Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation

By Ramsay Euan   Alnajim Jehan   Anantha Malathi   Taggar Aman   Thomas Anitha   Edwards Katarina   Karlsson Göran   Webb Murray   Bally Marcel  

Pharmaceutical Research, Vol. 23, Iss. 12, 2006-12 ,pp. : 2799-2808

Springer Publishing Company

Access to resources Recommend Favorite

Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates

By  

Current Drug Discovery Technologies, Vol. 13, Iss. 1, 2016-03 ,pp. : 2-15

Bentham Science Publishers

Access to resources Recommend Favorite